After her second round of chemo, with her ovarian cancer in remission, Marie started taking a mixed-media art class. She also began taking maintenance treatment with ZEJULA. As the weeks turned into months without cancer recurring, Marie’s art became her passion. Maintenance treatment with ZEJULA has given Marie time to create and exhibit her work at galleries. Her proudest composition is shared with you here.
ZEJULA is the first and only once-daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.1-3
More Time For More Women1
ZEJULA increased progression-free survival (PFS) for women with recurrent ovarian cancer following complete or partial response to platinum-based chemotherapy in a randomized, placebo-controlled phase 3 trial.1,4 At the time of the PFS analysis, limited overall survival data were available, with 17% of survival events occurring in the study (HR = 0.73; 95% Cl, 0.48-1.13), P= NS.1,5
- Median PFS 21.0 months in the gBRCAmut cohort with ZEJULA vs 5.5 months with placebo (HR= 0.26; 95% Cl, 0.17-0.41)1
- Median PFS 9.3 months in the non-gBRCAmut cohort with ZEJULA vs 3.9 months with placebo (HR= 0.45; 95% Cl, 0.34-0.61)1
Reference/H6: BRCA, breast cancer susceptibility gone: Cl, confidence interval; gBRCAmut, germline BRCA mutated; HR, hazard ratio; non-gBRCAmut, not germline BRCA mutated; NS, not significant; PARP. Poly(ADP-ribose) polymerase: PFS, progression-free survival.
In a double-blind, placebocontrolled phase 3 trial, ZEJULA improved PFS in both gBRCAmut and non-gBRCAmut.1,4
The safety and tolerability of ZEJULA were well-characterized in the phase 3 clinical trial.1,4
Dosing is convenient with ZEJULA, a once-daily oral medication.1
TESARO offers a suite of access and affordability solutions, including a co-pay assistance program for eligible patients.
Sign up to receive the latest news about ZEJULA